Olazagoitia-Garmendia Ane, Zhang Linda, Mera Paula, Godbout Julie K, Sebastian-DelaCruz Maialen, Garcia-Santisteban Iraia, Mendoza Luis Manuel, Huerta Alain, Irastorza Iñaki, Bhagat Govind, Green Peter H, Herrero Laura, Serra Dolors, Rodriguez Jose Antonio, Verdu Elena F, He Chuan, Bilbao Jose Ramon, Castellanos-Rubio Ainara
Department of Genetics, Physical Anthropology and Animal Physiology, University of the Basque Country (UPV-EHU), Leioa, Spain.
Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.
Gut. 2022 Jan;71(1):68-76. doi: 10.1136/gutjnl-2020-322566. Epub 2021 Feb 1.
Coeliac disease (CD) is a complex autoimmune disorder that develops in genetically susceptible individuals. Dietary gluten triggers an immune response for which the only available treatment so far is a strict, lifelong gluten free diet. Human leucocyte antigen (HLA) genes and several non-HLA regions have been associated with the genetic susceptibility to CD, but their role in the pathogenesis of the disease is still essentially unknown, making it complicated to develop much needed non-dietary treatments. Here, we describe the functional involvement of a CD-associated single-nucleotide polymorphism (SNP) located in the 5'UTR of in the inflammatory environment characteristic of the coeliac intestinal epithelium.
The function of the CD-associated SNP was investigated using an intestinal cell line heterozygous for the SNP, N6-methyladenosine (mA)-related knock-out and HLA-DQ2 mice, and human samples from patients with CD.
Individuals harbouring the risk allele had higher mA methylation in the 5'UTR of RNA, rendering greater XPO1 protein amounts that led to downstream nuclear factor kappa B (NFkB) activity and subsequent inflammation. Furthermore, gluten exposure increased overall mA methylation in humans as well as in in vitro and in vivo models.
We identify a novel mA-XPO1-NFkB pathway that is activated in CD patients. The findings will prompt the development of new therapeutic approaches directed at mA proteins and XPO1, a target under evaluation for the treatment of intestinal disorders.
乳糜泻(CD)是一种复杂的自身免疫性疾病,在遗传易感个体中发病。膳食中的麸质会引发免疫反应,目前唯一可用的治疗方法是严格的终身无麸质饮食。人类白细胞抗原(HLA)基因和几个非HLA区域与CD的遗传易感性有关,但其在疾病发病机制中的作用仍基本未知,这使得开发急需的非饮食疗法变得复杂。在此,我们描述了位于[具体基因名称]5'非翻译区(UTR)的一个与CD相关的单核苷酸多态性(SNP)在乳糜泻肠上皮特征性炎症环境中的功能参与情况。
使用该SNP杂合的肠道细胞系、N6 - 甲基腺苷(mA)相关敲除小鼠和HLA - DQ2小鼠以及CD患者的人类样本,研究与CD相关的SNP的功能。
携带风险等位基因的个体在[具体基因名称]RNA的5'UTR中有更高的mA甲基化,导致更多的XPO1蛋白量,进而导致下游核因子κB(NFkB)活性及随后的炎症反应。此外,麸质暴露增加了人类以及体外和体内模型中的总体mA甲基化。
我们确定了一种在CD患者中被激活的新的mA - XPO1 - NFkB途径。这些发现将促使针对mA蛋白和XPO1开发新的治疗方法,XPO1是一种正在评估用于治疗肠道疾病的靶点。